Rheb-Mutant Mammalian Cells for Higher Protein Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing proteins, particularly in mammalian cells, often result in low yields and inefficient secretion, which is a challenge for meeting the increasing demand for therapeutic proteins and maintaining cost-effectiveness in production.
Innovation Solution
Expressing proteins in cells with engineered Rheb proteins containing specific mutations, such as T23M, Y35N, and E40K, which enhance protein production and secretion by promoting mTORC1 signaling and conferring serum-independent growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If proteins are expressed in mammalian cells using conventional methods, then correct protein folding and appropriate post-translational modifications are achieved, but protein yields are low
Solution Approach 1:
The patent modifies the Rheb protein sequence by introducing specific mutations (T23M, Y35N, E40K) to change its functional parameters. These mutations enhance Rheb's ability to activate mTORC1 signaling, which in turn increases protein production capacity while maintaining proper folding and post-translational modifications through the mammalian cell system
Solution Approach 2:
The engineered Rheb protein acts as an intermediary that bridges the gap between conventional mammalian cell systems and high protein yield requirements. By modifying Rheb to constitutively activate mTORC1, it serves as a mediator that enables both correct protein processing and significantly improved protein yields simultaneously
2Reliability
If conventional mammalian cell systems are used for protein production, then appropriate post-translational modifications are provided, but secretion efficiency is poor
Solution Approach 1:
The patent changes the functional parameters of the Rheb protein through specific mutations (T23M, Y35N, E40K) that enhance its ability to activate mTORC1 signaling. This signaling enhancement directly improves secretion efficiency while preserving the mammalian cell system's capability for appropriate post-translational modifications
3Productivity
If protein production is scaled up to meet therapeutic demand, then production quantity increases, but manufacturing cost effectiveness decreases
Solution Approach 1:
The patent modifies cell line parameters by introducing Rheb mutations (T23M, Y35N, E40K) that constitutively activate mTORC1 signaling. This enables significantly higher protein production quantities from the same cell line, improving cost effectiveness by reducing the need for extensive cell line expansions and increasing manufacturing efficiency at scale
Data Source
AI summary
Methods for producing proteins, cells for producing proteins, and methods for producing cells with improved protein production are provided. Methods of producing a selected protein, including expressing the selected protein in a cell expressing a Rheb (Ras homologue enriched in brain) protein having an activity to increase protein production in the cell, and secreting the selected protein from the cell, thereby producing the protein are provided.